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SITOGENETIK MOLEKULAR MIELODISPLASTIK SINDROM  
- KAJIAN BERASASKAN HOSPITAL 
 
ABSTRAK 
 
Mielodisplastik Sindrom (MDS) adalah satu keadaan haematologi yang melibatkan 
sel-sel di dalam sum-sum tulang yang tinggi dan kiraan kandungan darah yang rendah. 
Tujuan kajian ini dijalankan adalah untuk mengenalpasti ketidaknormalan kromosom 
pada pesakit MDS menggunakan teknik sitogenetik dan “array-comparative genomic 
hybridization” (“array-CGH”) dan mengaitkannya dengan penemuan hematologi. 
Sejumlah 8 pesakit telah diambil untuk kajian ini. Keputusan sitogenetik menunjukkan 
6 kariotaip normal, satu kariotaip ketidaknormalan struktur (del(5)(q13q33) dan satu 
kariotaip ketidaknormalan kompleks (t(1;11), t(2;11), del(4p), del(5p), del(9p)). 
Menggunakan teknik “array-CGH”, ketidaknormalan yang diketahui, kompleks dan 
jarang berlaku/”cryptic” (<5 Mb) telah dikesan. Dalam kes ketidaknormalan yang 
diketahui, del5q (q13.1 - q13.2 (2.4 Mb)) dan  amplifikasi besar pada kromosom 8 
(p23.3-p11.1 (46.3 Mb) dan q11.1-q24.3 (98.7 Mb)) telah dikesan. Dalam 
ketidaknormalan kompleks, ketidaknormalan melibatkan saiz 0.7 Mb ke 98.7 Mb. Tiga 
pesakit telah menunjukkan persamaan dalam penemuan haematologi. Lima 
ketidaknormalan “cryptic” dikenalpasti dalam 3 pesakit (0.7 Mb ke 4.8 Mb). Secara 
rumusan, ketidaknormalan diketahui, kompleks dan jarang berlaku/”cryptic” telah 
dikesan. Perkaitan penemuan haematologinya boleh memberikan maklumat untuk 
menyediakan rawatan yang sesuai kepada pesakit. Penemuan ini juga boleh 
menyumbang kepada kepelbagaian ketidaknormalan kromosom di kalangan pesakit 
MDS.   
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MOLECULAR CYTOGENETICS OF MYELODYSPLASTIC SYNDROME 
– HOSPITAL BASED STUDY 
 
ABSTRACT 
 
Myelodysplastic Syndrome (MDS) is a haematological condition characterised by 
hypercellular bone marrow and low peripheral blood counts. The objectives of this 
study were to identify chromosomal aberration using conventional cytogenetics and 
array comparative genomic hybridisation (array-CGH) in MDS patients and correlate 
with its’ haematological findings. A total of 8 patients were recruited.  Cytogenetic 
results revealed six normal karyotypes, a karyotype with structural abnormalities 
(del(5)(q13q33) and a karyotype with complex rearrangement (t(1;11), t(2;11), 
del(4p), del(5p), del(9p)). By array-CGH technique, known cytogenetic aberrations, 
complex chromosome aberrations and rare/cryptic aberrations (<5 Mb) were 
detected. In the case of common aberrations, del5q (q13.1 - q13.2 (2.4 Mb)) and 
large amplification of chromosome 8 (p23.3-p11.1 (46.3 Mb) and q11.1-q24.3 
(98.7 Mb)) were detected. In complex aberrations, the aberrations involved from 
0.7 Mb to 98.7 Mb in size. These patients showed similarities of haematological 
findings. Five cryptic aberrations were identified in 3 patients (0.7 Mb to 4.8 Mb). 
As a conclusion, common, complex and cryptic aberrations were detected in MDS 
patients. The associated haematological findings could provide useful information to 
stratify the suitability of the treatments for the patients. These findings also might 
contribute to the heterogeneity of choromosomal aberrations in MDS patients. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Background 
 
Myelodysplastic Syndrome (MDS) is a haematological medical condition that 
involves ineffective production of the myeloid cells. It is characterised by 
progressive reduction in myeloid cells in the peripheral blood, reflecting defects in 
red blood cells (RBC), white blood cells (WBC) or platelets maturation.  
 
Myelodysplastic Syndrome (MDS) are much more common in elderly. The incidence 
of MDS varies by population, 3.5–12.6 per 100 000 population per year with 15-89 
per 100, 000 in elderly per year (Aul et al., 1998; Sole et al., 2000; Cogle et al., 
2011; Guillermo et al., 2011). MDS rarely affect individuals younger than age 50, 
unless preceeded by chemotherapy or radiation for another malignancy.  
 
The overall incidence of MDS is slightly higher in males than in females (1.5 to 2.1). 
In people over 70 years of age, incidence rates are about 20 to 40 per 100, 000 
population, suggesting that MDS is at least as common as chronic lymphocytic 
leukaemia or multiple myeloma (Ulrich et al., 2004). 
 
There are two categories of MDS; de novo MDS and secondary MDS. In de novo 
MDS, a transforming event affects a pluripotent or multipotent progenitor cell in the 
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bone marrow, conferring a growth advantage upon it and eventually establishing 
clonal haematopoiesis.  
 
However, secondary MDS is “therapy-related MDS/AML” following exposure to 
alkylating agents is the only clear etiological factor thus identified. Increasing 
evidence for exposure to benzene and radiation and the development of MDS is 
emerging (Pagano et al., 2006). Benzene haematotoxicity is mediated via both 
genotoxic and non-genotoxic mechanisms, leading to aplasia, apoptosis and initiation 
(via genetic mutation) of clonal disorders such as MDS (Rinsky et al., 1987). 
 
Many patients in the early stages of MDS experience no symptoms at all. A routine 
blood test may reveal a reduced red cell count (anaemia), sometimes along with 
reduced white cell (leukopaenia) and/or platelet counts (thrombocytopaenia). On 
occasion, the white cell and platelet counts may be low while the red cell count 
remains normal. In the early stages of this disease, the counts are usually not so 
reduced that they produce symptoms. However, some patients, particularly those 
with blood cell counts well below normal, experience definite symptoms (Mary, 
2005).  
 
Anaemic patients generally experience fatigue and report that they are tired much of 
the time and have no energy. About 80% (Peter & Bennet, 2006) of patients are 
anaemic when they are initially diagnosed with MDS. Anaemia varies in its severity. 
In mild anaemia, patients may feel well or just slightly fatigued. In moderate 
anaemia, almost all patients experience some fatigue, which may be accompanied by 
heart palpitations, shortness of breath, and pale skin. In severe anaemia, almost all 
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patients appear pale and suffer severe fatigue and shortness of breath. Because severe 
anaemia reduces blood flow to the heart, older patients may be more likely to 
experience cardiovascular symptoms, including chest pain (Guillermo et al., 2011).  
 
A reduced white cell count lowers the body’s resistance to bacterial infection. 
Patients with neutropaenia may be susceptible to skin infections, sinus infections, 
lung infections or urinary tract infections.  Fever may accompany these infections 
(Mary, 2005). 
 
Patients with low platelets count have an increased tendency to bruise and bleed even 
after minor bumps and scrapes. Bruises can be dramatic, some as large as the palm of 
the hand (Mary, 2005).  
 
Recently, the classification of this disease has been refined to include new scientific 
and clinical information – including cytogenetics. Based on the studies carried out, 
cytogenetic abnormalities have been observed in 40-50% of patients with MDS 
(Athena et al., 2003; James et al., 2009) and the karyotype may exhibit differences 
between primary (de novo) and secondary MDS.  
 
The disease course varies widely from patient to patient, from indolent to aggressive 
with swift progression to acute myeloid leukaemia (AML) in 30% of cases (Besa et 
al., 2009). Patients with favourable prognoses are often associated with normal 
karyotype or a single chromosomal abnormality.  
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The prognosis becomes worse when it is associated with complex karyotype (>3 
abnormalities). It is found that, a strong association between numbers of 
abnormalities with poor prognostic value in patients with primary MDS (David et al., 
2013). The results also included shorter survival rate and high risk progression 
toward AML.  
 
Studies also showed that occurrence of rare cytogenetic abnormalities have a 
relatively grim clinical outcome. For example, Wang et al. (2010) suggested that rare 
occurrence of trisomy 11 in MDS is best considered as a high-risk cytogenetic 
abnormality in MDS prognostication due to its clinical aggressiveness towards 
evolving AML with myelodysplasia-related changes. Although various chromosomal 
abnormalities have been identified in patients with MDS, the specific genes that play 
roles in the disease development are yet to be identified (Bernadette et al., 2007). 
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1.2 Justification of the Study 
 
A significant portion of MDS patients have chromosomal abnormalities. Although 
wide researches on MDS have been carried out, the prevalence of local MDS data is 
not available. Several case reports and a single scientific study have been reported 
before (Marini et al., 2005; Yin et al., 2011; Zainina et al., 2006; Mohadese et al., 
2012). 
 
Reference to Health Informatics Center, Ministry of Health (MOH) found that the 
data is grouped together under D37-D48 “Neoplasm of uncertain or unknown 
behaviour” based on International Classification of Diseases-10 (ICD-10) which has 
made it difficult to categorise the exact incidence of this disorder. Additionally, 
research on it has not been done extensively. Based on a haematological study 
carried out at Hospital Kepala Batas/Advanced Medical and Dental Institute from 
November 2003 to December 2007, only 2 cases were confirmed as MDS from 3804 
Peripheral Blood Film (PBF) reviewed. The cases were confirmed by Peripheral 
Blood Film (PBF) & Bone Marrow Aspiration and Trephine Biopsy (BMAT). The 
objective of this was to obtain the profiles and clinical features of MDS (Lee et al., 
2009).  
 
Therefore, in order to understand the cause of this disorder comprehensively, this 
study was carried out to investigate the findings of chromosomal aberrations in 
patients with MDS using available cytogenetics technique i.e conventional 
cytogenetics and array-based Comparative Genomic Hybridisation (array-CGH). 
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1.3 Hypothesis 
 
Many chromosomal aberrations have been associated with the development of MDS. 
Therefore, it is hypothesised that the chromosomal aberrations in patients with MDS 
using conventional cytogenetics techniques and array-CGH techniques will be 
clarified. 
 
1.4General Objective 
 
The general objective of this study was to investigate chromosomal aberrations in 
patients with MDS with its associated haematological findings. 
 
1.5 Specific Objectives 
 
1. To identify common and cryptic aberrations in patients with Myelodysplastic 
Syndrome (MDS) using conventional cytogenetic and array-based 
Comparative Genomic Hybridisation (array-CGH) techniques.   
2. To associate haematological and clinical findings and molecular cytogenetics 
in patients with MDS.  
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1.6 Literature Review 
 
1.6.1 Myelodysplastic Syndrome (MDS) 
 
Myelodysplastic syndrome (MDS) is a group of conditions in which there is 
disordered maturation (dysplasia) in one or more of the myeloid cell lineage. Blood 
cell production from the dysplastic cells is ineffective and therefore, may lead to 
anaemia, thrombocytopaenia or neutropaenia. 
 
The population of dysplastic cells represents an abnormal clone in the stem cell 
which is stable for a variable period (sometimes for several years). It may generate 
new clones associated with increasingly ineffective haematopoiesis or increasing 
dysfunction of mature cells (Bernadette et al., 2007). The majority of the patients are 
elderly with many abnormalities that may be seen on the blood film; often only a 
single abnormality may be found at diagnosis and others appear later.  Some patients 
are diagnosed incidentally as a consequence of having a blood count for unrelated 
reason. Others present with symptoms referable to anaemia, thrombocytopaenia or 
neutropaenia and to functional abnormalities of neutrophils and platelets (Mary, 
2005).  
 
The signs and symptoms of MDS result from the infiltration of the blasts into bone 
marrow and peripheral blood. A history of infections, bleeding, weight loss or 
cardiovascular symptoms may be the complaints made by the patients. Signs of 
anaemia are pale skin and easy fatigability. Infections are caused by reduction of 
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white blood cells (WBC) and thrombocytopaenia may be a feature as manifested by 
gum bleeding and easy bruising (Bernadette et al., 2007). 
 
Clonal disorders in MDS has been proposed to progress through the stages of 
tumorigenesis, in which the unstable haematopoietic stem cells are susceptible to 
genetic lesion. Once a stem cell gains a dominant mutation over the normal cell 
growth, the cell shows clonal evolution to become much more susceptible to further 
multiple genetic mutations. At this stage it is most likely accompanied by a high rate 
of cell death. Finally, it will lead to malignant transformation with an increase in 
leukemic blast cells and evolution to acute myeloid leukaemia (Aul et al., 1998; 
Hisamaru, 2003). Though, the initial event that causes this primary lesion remains 
unknown. 
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1.6.2 Classification of MDS 
 
At present, MDS is classified according to the two most common systems – French 
American British (FAB) and World Health Organisation (WHO). 
 
FAB scheme divided MDS into five subgroups, based on percentage of blast cells in 
the peripheral blood and bone marrow, the presence of ringed sideroblasts in the 
bone marrow and the monocyte count in the peripheral blood (Table 1.1) (Bennet et 
al., 1982).  
 
Based on biology, immunophenotyping, genetic and clinical features, WHO 
classified MDS in the following seven groups: refractory cytopaenias with unilineage 
dysplasia (RCUD), refractory anaemia with ring sideroblasts (RARS), refractory 
anaemia with multilineage dysplasia (RCMD),  refractory anaemia with excess 
blasts-1 (RAEB-1), refractory anaemia with excess blasts-2 (RAEB-2), MDS, 
unclassifiable (MDS-U) and MDS associated with isolated del(5q) (James et al., 
2009). 
 
Although there are many differences between adult and paediatric MDS, neither 
FAB nor WHO have used age in their classification. The three significant differences 
between FAB and WHO classifications are noted here. First, WHO lowered the 
percentage of blasts required for MDS diagnosis to at least 20% blasts instead of 
30% as recorded in FAB. Second, the inclusion of multilineage dysplasia subtype in 
the cases of patients with cytopaenia. And third, the addition of MDS with isolated 
del(5q) which is lacking in FAB. WHO seems to be more clinically useful than FAB 
10 
 
classification as the system recommends using all available data including biologic, 
immunophenotypic, genetic and clinical features for a proper identification. 
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Figure 1.1. MDS constitute a complex range of stem-cell diseases. The 
myelodysplastic syndromes (MDS) cell clone can suppress normal haematopoiesis 
(a) directly or indirectly through stroma. Stem-cell defects can result in single lineage 
deficiency (refractory anaemia and ringed sideroblasts (RARS; b)) or multiple-
lineage deficiencies (refractory anaemia with excess blasts (RAEB; c)). MDS stem-
cell diseases (d) might seem like de novo acute myeloid leukaemia (AML), however, 
the two are distinguishable. For example (e), cytopaenias in de novo AML can be 
more restricted owing to a failure in differentiation. HSC: haematopoietic stem cell 
(Reproduced from James et al., 2009). 
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Table 1.1.FAB classification of MDS (Reproduced from Bennet et al., 1982). 
Category Dysplasia 
% BM 
Blasts 
%PB 
Blasts 
 
Refractory anaemia (RA) 
 
Erythroid 
 
<5 
 
<1 
 
Refractory anaemia with ring 
sideroblasts (RARS) 
 
Erythroid 
 
<5 
 
<1 
 
Refractory anaemia with excess blasts 
(RAEB) 
 
2 or more lineages 
 
5-20 
 
0-4 
 
Refractory anaemia with excess blasts in 
transformation (RAEB-T) 
 
Usually 2 or more 
lineages 
 
21-30 
 
>5 
 
Chronic myelomonocytic leukaemia 
(CMML) 
 
 
Variable >1 x 109/L 
monocytes 
 
<20 
 
>5 
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Table 1.2.WHO classification of MDS (Reproduced from James et al, 2009). 
Disease entity Blood findings Bone marrow findings 
Refractory cytopaenias with 
unilineage dysplasia (RCUD): 
refractory anaemia (RA), 
refractory neutropaenia (RN), 
refractory thrombocytopaenia (RT) 
Unicytopaenia or 
bicytopaeniaa 
No or rare blasts 
(<1%)b 
Unilineage dysplasia: ≥10% of 
the cells in one myeloid 
lineage , <5% blasts, 15% of 
erythroid precursors are ring 
sideroblasts 
Refractory anaemia with ring 
sideroblasts (RARS) 
Anaemia 
No blasts 
≥15% of the erythroid 
precursors are ring 
sideroblasts.  
Dyserythropoiesis only  
<5% blasts 
Refractory anaemia with 
multilineage dysplasia (RCMD) 
Cytopaenia(s), no or 
rare blastsb  
No Auer rods  
<1 ×109/L monocytes 
Dysplasia in >10% of cells in 
2 or more lineages  
<5% blasts in marrow  
No Auer rods  
<1 × 109/L monocytes 
Refractory anaemia with excess 
blasts-1 (RAEB-1) 
Cytopaenia(s)  
<5% blasts  
No Auer rods  
<1 ×109/L monocytes 
Unilineage or multilineage 
dysplasia  
5–9% blasts  
No Auer rods 
Refractory anaemia with excess 
blasts-2 (RAEB-2) 
Cytopaenia(s)  
5–19% blasts  
Auer rods ±c 
<1 × 109/L 
monocytes 
Unilineage or multilineage 
dysplasia  
0–19% blasts  
Auer rods ±c 
MDS, unclassifiable (MDS-U) Cytopaenias  
<1% blastsb 
Unequivocal dysplasia in less 
than 10% of cells in one or 
more myeloid lines when 
accompanied by a cytogenetic 
abnormality considered as 
presumptive evidence for a 
diagnosis of MDS <5% blasts 
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MDS associated with isolated 
del(5q) 
Anaemia 
Usually normal to 
elevated platelets  
No or rare blasts 
Normal to increased 
megakaryocytes with 
hypolobulated nuclei <5% 
blasts del(5q) is the sole 
cytogenetic abnormality  
No Auer rods 
aBicytopaenia may be occasionally observed. Cases with pancytopenia should be classified as MDS-
U.  
b
 If marrow blast % is less than 5%, but there are 2–4% myeloblasts in blood, the diagnosis is RAEB-
1. Cases of RCUD and RCMD with 1% blasts in blood are classified as MDS-U.  
c
 Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be 
classified as RAEB-2. 
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1.6.3 Cytogenetic Abnormalities 
 
Genetic aberrations, as losses of genetic material (deletions) or localised gains that 
affect certain region of the genome have been shown to be the basis of many 
diseases. Occurrence of one or more of genetic alterations in the genome that lead to 
changes in DNA sequence copy number have been well documented to characterise 
the prevalence of rare and common diseases.  
 
In MDS, it has been observed cytogenetic abnormalities in 40 - 50% of patients with 
MDS and the karyotypes may differ between primary (de novo) and secondary MDS 
(Athena et al., 2003; James et al., 2009). The differences may be observed on initial 
bone marrow observation or during evolution of the disease (James et al., 2009).  
 
Frequent chromosome abnormalities that have been observed in studies were del(5q), 
monosomy 7/del(7q), trisomy 8, del(20q) and complex karyotypes (CK) (>3 
abnormalities) (Hisamaru, 2002; Martı´nez-Ramı´rez et al., 2004; Look  2005; 
Martı´nez-Ramı´rez et al., 2005). According to International Prognostic Scoring 
System (IPSS), the prognosis of these recurrence cytogenetic abnormalities is 
described here: del(5q) and del(20q) - good prognosis; del(7q) and trisomy 8 - 
intermediate prognosis, monosomy 7 - poor prognosis and CK – very poor prognosis. 
CK also have the highest risk to evolve to AML.  
 
Del(5q) and monosomy 7/del(7q) occur in about 20% of MDS patients and the 
incidence increased to 50% in secondary MDS (Cordoba et al. 2012; Hisamaru, 
2003; West et al., 2000).  This is due to these patients have been exposed to benzene. 
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Benzene derivative metabolite has been proven to induce deletion of chromosome 5 
and 7 in human CD34+CD19- bone marrow cells (Stillman et al., 1999; Pagano et al., 
2006). CK also has shown high incidence in secondary MDS at about 20% 
incidences (West et al., 2000). Although many chromosomal abnormalities have 
been identified in patients with MDS, the genes involved in the disease development 
are yet to be identified (Bernadette et al., 2007).  
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Table 1.3. IPSS Cytogenetic risk groups (Greenberg et al., 2012). 
Prognosis Cytogenetic abnormalities 
Very good -Y, del(11q) 
Good 
Normal, del(5q), del(12p), del(20q), double 
including del(5q) 
Intermediate 
del(7q), +8, +19, inv(17q), any other single or 
double independent clones 
Poor 
-7, inv(3)/t(3q)/del(3q), double including -7/del(7q), 
Complex: 3 abnormalities 
Very poor Complex: >3 abnormalities 
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1.6.3.1 The 5q- Syndrome 
 
The 5q- abnormality is the most common abnormality found and constituted of more 
than 20% in MDS patients (Hisamaru, 2003). The diagnosis was restricted to the 
cases of isolated interstitial del(5q), without excess blasts in the bone marrow (<5%) 
(James et al., 2009). It was first reported as a type of refractory anaemia with clinical 
features; female predominance (unlike other MDS), macrocytosis, erythroid 
hypoplasia, frequent thrombocytosis and dysmegakaryopoiesis (Van den et al., 
1985).  A summary of the clinical and haematologic features that are specific to the 
5q- syndrome subtype of MDS is shown in Figure 1.2. 
 
The breakpoints within a large region of 5q are highly variable among patients, but 
the most critical region of deletion is supposed to lie between 5q13 and 5q33 
(Kanehira et al., 2009, Aristoteles et al., 2006). Several genes encoding haemopoietic 
growth factors and receptors, comprising IL-3, IL-4, IL-5, M-CSF (CSF-I), GM-CSF, 
and the receptor for M-CSF (CSF-IR), are localised to the long arm of chromosome 
5. It is believed that deletion of one or more of these genes may be critical to the 
pathogenesis of the associated MDS (Boultwood, 2000). 
 
By the International Prognostic Scoring System, patients with isolated deletion 5q 
have a relatively good prognosis with low risk of transformation to AML and are 
assigned to the low-risk MDS category. Giagounidis et al. (2004) reported that a 
median overall survival of 107 months at a median follow-up of 53 months, and a 
low probability of transformation to acute myeloid leukaemia These patients 
typically have an isolated 5q deletion and a medullary blast count <5%.  
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Despite the low risk of transformation to AML in these patients, the dependence on 
RBC transfusions often has a negative effect on morbidity and mortality (Boultwood 
et al., 2000; Giagounidis et al., 2004). Moreover, patients with deletion 5q show 
excellent response rates when treated with the immunomodulatory drug lenalidomide 
(List et al., 2006). However, it is thought that the presence of additional 
chromosomal abnormalities and/or high medullary blast percentage in patients with a 
5q deletion can have a negative effect on disease progression and survival. 
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Figure 1.2. Clinical and pathologic characteristic of 5q-syndrome (Adapted from 
Aristoteles et al., 2006). 
Clinical Presentation  
 
• Older age 
• Female predominance (7:3 female to male ratio) 
• Diagnosis of refractory anaemia 
• Low risk to leukemic progression 
• Good prognosis 
 
Haematologic and Pathologic Presentation 
 
• Macrocytic anaemia 
• Modest leukopaenia 
• Normal/High platelets counts 
• 5q deletion as the sole karyotypic abnormality 
• Bone marrow erythroid hypoplasia 
• Hypolobulated megakaryocytes in bone marrow 
• <5% bone marrow blasts count 
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1.6.3.2 Monosomy 7 or -7q 
 
Monosomy 7 and -7q are among the most frequent chromosomal abnormalities in 
MDS. It is associated with poor prognosis in terms of survival or leukaemic 
evolution. This abnormality may occur de novo or be secondary to an exposure to 
chemical mutagens prior to chemotherapy treatments with alkylating agents. In IPSS, 
monosomy 7 or -7q is classified as poor prognostic criteria, characterised by 
infectious susceptibility, quick aggravation and treatment resistance. Abnormalities 
involving chromosome 7 occur in approximately 20% of patients with MDS and 
clonal cytogenetic abnormalities and usually include deletion of part of the long arm 
of chromosome 7 (-7q), total loss of chromosome 7 (monosomy 7), or translocations 
involving chromosome 7. 
 
Reports have argued that patients who have -7q as a single abnormality overall tend 
to have a better prognosis than those who have isolated monosomy 7 (Haase et al., 
2007; Pozdnyakova et al., 2008). These findings tend to suggest that patients who 
have MDS with isolated -7q should not be classified in the same group as those who 
have MDS with monosomy 7. However, those studies involved a very limited 
number of patients with MDS and chromosome 7 anomalies, and the observed 
differences in survival between isolated del(7q) and single monosomy 7 were not 
statistically significant. 
 
Given the high heterogeneity of the break points on 7q, it is suggested that multiple 
genes are involved in the pathogenesis of myeloid disorder (Brezinova et al,. 2007). 
Although genes on chromosome 7 that are responsible for the disease phenotype are 
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not yet been identified, a critical region at locus 7q22.1 has been suggested to have 
significant role in myeloid malignancies (Johnson et al., 1996). Cordoba’s et al. 
(2012) study also confirmed that 7q22 was the most commonly deleted region in 
patients with isolated del7q. A potential myeloid tumor suppressor gene, PIK3CG, 
has been identified in this locus, but is unlikely to act as a recessive tumour-
suppressor gene in MDS with monosomy 7 (Kratz et al., 2002).  
 
MDS with chromosome 7 abnormalities, have also been shown to associate with 
somatic mutations of the RUNX1 gene, and so far monosomy 7 and 
der(1;7)(q10;p10) have been regarded as similar cytogenetic entities because they 
both result in loss of 7q. However, in recent study by Westman & Mette (2013) has 
shown that the other gene that was significantly asscociated with this subgroup. IDH, 
has shown to have mutation up to 37% of the cases with der(1;7)(q10;p10) whereas 
in monosomy 7, mutations of RUNX1 and DNMT3A genes were equally distributed 
between the two subgroups (Westman & Mette, 2013). This study was in line with 
recent findings of different clinical outcomes for patients with der(1;7)  and 
monosomy 7/-7q (Ganster et al.,  2013).  
 
In paediatric cases, MDS with monosomy 7 or -7q was reported in a few occasions 
associated with poor prognosis and progression to acute myeloid leukaemia as well 
as acute lymphoid leukaemia (Aktas & Tuncbilek, 2006). Recently, it was 
demonstrated that patients who had MDS with isolated -7q had some distinct 
clinical-pathologic characteristics as well as better survival than patients who had 
MDS with monosomy 7 (Cordoba et al., 2012). 
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1.6.3.3 Trisomy 8 (+8) 
 
According to the IPSS, sole +8 is categorised as intermediate cytogenetic subgroup. 
But as some MDS patients with +8 perhaps progress quickly to acute leukaemia and 
have shorter survival (Ma et al., 2012), some reports have suggested that +8 should 
be categorised into poor risk cytogenetic group. Although trisomy 8 as the sole 
chromosome aberration is the most common numerical abnormality in acute myeloid 
malignancies, little is known about its pathogenic effects. In a study by Paulsson et al 
(2006), who performed high-resolution genome-wide array comparative genomic 
hybridisation (array-CGH) in MDS cases with trisomy 8 as the sole cytogenetic 
aberration, have revealed that +8 is not always the primary genetic event and 
suggested that +8 is not sufficient for leukaemogenesis.  
 
1.6.3.4 Rare Occurrence Chromosomal Abnormalities 
 
Rare occurrences of cytogenetic abnormalities have been observed in numerous 
studies. A study detected cryptic aberrations of 12p-, 13q-, +21 and +11 in 32 
primary MDS patients (Rolf et al., 2002). Another study found chromosomal 
anomalies of del(12)(p12p13), involvement of 13q and del(20)(q11q12) (Sendiet al. 
2002). Other rarer abnormalities detected  were abnormalities in chromosome 3 
using conventional cytogenetics (Pozdnyakova et al., 2008). Pozdnyakova et al. 
(2008) also reported that +11 as the sole cytogenetics anomaly whose patients died 
within 21 months after the diagnosis. Other abnormalities found in this study were 
del(12p), del(11)(q23), and +19. In case of +11, a study by Wang et al. (2010) has 
suggested a strong correlation between +11 and early/evolving AML.  
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As described above, one complicating factor in the diagnosis of MDS is the 
heterogeneity of cytogenetic abnormalities. Unlike chronic myeloid leukaemia for 
example, in which there is one dominant cytogenetic abnormality, t(9;22), numerous 
cytogenetic abnormalities are associated with MDS. Even though all of these 
findings were relatively rare, these cytogenetic abnormalities cannot be looked upon 
lightly due to its different interpretation of its clinical aggressiveness. Accurate, 
timely diagnosis is important because of the risk of transformation to AML. Overall, 
the prognosis is poor for patients with MDS, with three-year survival rates estimated 
to be <50% (Rollison & List, 2004). 
 
1.6.4 Methods of Detection 
 
There are several methods to detect chromosomal abnormalities in MDS patients i.e. 
cytogenetics, comparative genomic hybridisation (CGH) and array-comparative 
genomic hybridisation (array-CGH).  
 
1.6.4.1 Cytogenetics Analysis 
 
Cytogenetics is the most widely used method for the identification of chromosome 
aberrations. Cytogenetics involves karyotyping which organises all chromosomes by 
homology, size and shape; providing an overview of the whole genome and detects 
both numerical and structural chromosomal aberrations (overall resolution is 10 Mega 
bases (Mb); breakpoint resolution is 5 to 15 Mb) (Steven & Martha, 2006).  
 
